Lowdell Mark William's Form 4/A amendment
AmendedInmune Bio, Inc. (INMB) · filed Apr 24, 2024
- Accession no.
- 0001213900-24-035721
- Filed
- Apr 24, 2024, 2:08 PM ET
- Trade date
- Apr 19, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Apr 23, 2024
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $120.0K. It was filed 5 days after the trade.
This amendment replaces 0001213900-24-035472 (filed Apr 23, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lowdell Mark WilliamCIK 0001767037 | Officer (Chief Scientific Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 19, 2024 | Common Stock | PPurchaseAcquired | +14,423 | $8.32 | +$119,999.36 | 1,510,806 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 19, 2024 | Common Stock | PPurchaseAcquired | +14,423 | $0.125 | +$1,802.88 | 14,423 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $121,802.24 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.
Remarks
The original Form 4, filed on April 23, 2024 is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the transaction as an award in column 3 of Table I and column 4 of table II instead of a purchase. The reporting person purchased the securities in a registered direct transaction from the Company.